中国临床药理学杂志2025，Vol.41Issue(8)：1180-1185,6.DOI:10.13699/j.cnki.1001-6821.2025.08.023
细胞周期蛋白依赖性激酶4/6抑制药吡洛西利的研究进展
Research progress of-bireociclib-a new cyclin-dependent kinase 4 and 6 inhibitor
摘要
Abstract
Bireociclib,a novel selective cyclin-dependent kinase 4/6(CDK4/6)inhibitor,demonstrates significant therapeutic benefits in hormone receptor(HR)-positive,human epidermal growth factor receptor 2(HER2)-negative advanced or metastatic breast cancer.As a monotherapy in later-line treatment,it substantially improves objective response rate(ORR),prolongs median progression-free survival(PFS),and extends median overall survival(OS).When combined with fulvestrant as a second-line therapy,it significantly delays disease progression and reduces mortality risk.Currently,marketing authorization applications for Bireociclib monotherapy in breast cancer and its combination with fulvestrant for advanced breast cancer have been submitted to National Medical Products Administration.The phase Ⅲclinical trial investigating its first-line use in combination with letrozole/anastrozole is nearing completion.This article comprehensively reviews Bireociclib's molecular structure,pharmacodynamic properties,pharmacokinetic characteristics,etc.关键词
吡洛西利/细胞周期蛋白依赖性激酶4/6抑制药/乳腺癌/药理学/临床研究Key words
bireociclib/cyclin-dependent kinase 4/6 inhibitor/breast cancer/pharmacology/clinical study分类
医药卫生引用本文复制引用
赵盼,周慧敏,陈博,王凤,李嘉逵,马西凤..细胞周期蛋白依赖性激酶4/6抑制药吡洛西利的研究进展[J].中国临床药理学杂志,2025,41(8):1180-1185,6.基金项目
国家十三五"重大新药创制"科技重大专项课题资助项目(2018ZX09711002-011-027) （2018ZX09711002-011-027）
